Haematological malignancies: At the forefront of immunotherapeutic innovation

Nature Reviews Cancer

Volumn 15, Issue 4, 2015, Pages 201-215

  Bachireddy, Pavan ^a,b,c   Burkhardt, Ute E ^a   Rajasagi, Mohini ^a,b,d   Wu, Catherine J ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; CANCER VACCINE;

ALLOIMMUNITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN PRESENTATION; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL FEATURE; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG TARGETING; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMORAL IMMUNITY; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MYELOID DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; SUPPRESSOR CELL; T LYMPHOCYTE; TH1 CELL; TUMOR IMMUNITY; TUMOR IMMUNOLOGY; TUMOR MICROENVIRONMENT; ANIMAL; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; IMMUNOTHERAPY;

ANIMALS; CANCER VACCINES; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOTHERAPY;

EID: 84925797465     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3907     Document Type: Review

References (212)

1. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nature Rev. Cancer 12, 252-264 (2012).
2. Gattiker, H. H., Wiltshaw, E. & Galton, D. A. Spontaneous regression in non-Hodgkin's lymphoma. Cancer 45, 2627-2632 (1980).
3. Del Giudice, I. et al. Spontaneous regression of chronic lymphocytic leukemia: clinical and biologic features of 9 cases. Blood 114, 638-646 (2009).
4. Nadler, L. M. et al. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J. Clin. Invest. 67, 134-140 (1981).
5. Feuerer, M. et al. Bone marrow as a priming site for T cell responses to blood-borne antigen. Nature Med. 9, 1151-1157 (2003).
6. Cardoso, A. A. et al. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood 88, 41-48 (1996).
7. Costello, R. T. et al. Regulation of CD80/B7-1 and CD86/B7 2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition. Eur. J. Immunol. 28, 90-103 (1998).
8. Brouwer, R. E. et al. Expression and induction of costimulatory and adhesion molecules on acute myeloid leukemic cells: implications for adoptive immunotherapy. Exp. Hematol. 28, 161-168 (2000).
9. Riemersma, S. A. et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood 96, 3569-3577 (2000).
10. Steidl, C. et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 471, 377-381 (2011).
11. Zitvogel, L., Galluzzi, L., Smyth, M. J. & Kroemer, G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 39, 74-88 (2013).
12. Apetoh, L. et al. Toll-like receptor 4 dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nature Med. 13, 1050-1059 (2007).
13. Burger, J. A. et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor 1. Blood 96, 2655-2663 (2000).
14. Jia, L. et al. Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia. Blood 123, 1709-1719 (2014).
15. Fridman, W. H., Pages, F., Sautes-Fridman, C. & Galon, J. The immune contexture in human tumours: impact on clinical outcome. Nature Rev. Cancer 12, 298-306 (2012).
16. Burger, J. A. et al. High-level expression of the T cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 113, 3050-3058 (2009).
17. Sivina, M. et al. CCL3 (MIP 1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood 117, 1662-1669 (2011).
18. Bagnara, D. et al. A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood 117, 5463-5472 (2011).
19. Greaves, P. et al. Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. Blood 122, 2856-2863 (2013).
20. Hussell, T., Isaacson, P. G., Crabtree, J. E. & Spencer, J. The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet 342, 571-574 (1993).
21. Umetsu, D. T., Esserman, L., Donlon, T. A., DeKruyff, R. H. & Levy, R. Induction of proliferation of human follicular (B type) lymphoma cells by cognate interaction with CD4+ T cell clones. J. Immunol. 144, 2550-2557 (1990).
22. Kiaii, S. et al. Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation. J. Clin. Oncol. 31, 2654-2661 (2013).
23. Guilloton, F. et al. Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2 dependent recruitment and polarization of monocytes. Blood 119, 2556-2567 (2012).
24. Vega, F. et al. The stromal composition of malignant lymphoid aggregates in bone marrow: variations in architecture and phenotype in different B-cell tumours. Br. J. Haematol. 117, 569-576 (2002).
25. Scott, D. W. & Gascoyne, R. D. The tumour microenvironment in B cell lymphomas. Nature Rev. Cancer 14, 517-534 (2014).
26. Palumbo, A. & Anderson, K. Multiple myeloma. N. Engl. J. Med. 364, 1046-1060 (2011).
27. Kim, J. et al. Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells. Br. J. Haematol. 158, 336-346 (2012).
28. Kawano, M. et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332, 83-85 (1988).
29. Bahlis, N. J. et al. CD28 mediated regulation of multiple myeloma cell proliferation and survival. Blood 109, 5002-5010 (2007).
30. Murray, M. E. et al. CD28 mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma. Blood 123, 3770-3779 (2014).
31. Noonan, K. et al. A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 116, 3554-3563 (2010).
32. H17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 115, 5385-5392 (2010).
33. Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Med. 10, 942-949 (2004).
34. Bates, G. J. et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J. Clin. Oncol. 24, 5373-5380 (2006).
35. + cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J. Clin. Oncol. 24, 5052-5059 (2006).
36. Carreras, J. et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 108, 2957-2964 (2006).
37. + regulatory T cells and hematologic malignancies. Front. Biosci. (Schol. Ed.) 2, 980-992 (2010).
38. Greaves, P. et al. Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J. Clin. Oncol. 31, 256-262 (2013).
39. Carreras, J. et al. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J. Clin. Oncol. 27, 1470-1476 (2009).
40. Coiffier, B. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 235-242 (2002).
41. Cheson, B. D. & Leonard, J. P. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N. Engl. J. Med. 359, 613-626 (2008).
42. Sliwkowski, M. X. & Mellman, I. Antibody therapeutics in cancer. Science 341, 1192-1198 (2013).
43. Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S. & Winter, G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522-525 (1986).
44. Riechmann, L., Clark, M., Waldmann, H. & Winter, G. Reshaping human antibodies for therapy. Nature 332, 323-327 (1988).
45. Clynes, R. A., Towers, T. L., Presta, L. G. & Ravetch, J. V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nature Med. 6, 443-446 (2000).
46. Park, S. et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18, 160-170 (2010).
47. Weng, W. K. & Levy, R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21, 3940-3947 (2003).
48. Beers, S. A., Chan, C. H., French, R. R., Cragg, M. S. & Glennie, M. J. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin. Hematol. 47, 107-114 (2010).
49. Wierda, W. G. et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J. Clin. Oncol. 28, 1749-1755 (2010).
50. Reagan, J. L. & Castillo, J. J. Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia. Expert Rev. Anticancer Ther. 11, 151-160 (2011).
51. Goede, V. et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N. Engl. J. Med. 370, 1101-1110 (2014).
52. Golay, J., Manganini, M., Rambaldi, A. & Introna, M. Effect of alemtuzumab on neoplastic B cells. Haematologica 89, 1476-1483 (2004).
53. Pro, B. et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J. Clin. Oncol. 30, 2190-2196 (2012).
54. Younes, A. et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J. Clin. Oncol. 30, 2183-2189 (2012).
55. Tai, Y. T. et al. Anti CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 112, 1329-1337 (2008).
56. Zonder, J. A. et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 120, 552-559 (2012).
57. Lonial, S. et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J. Clin. Oncol. 30, 1953-1959 (2012).
58. Ocio, E. M. et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 28, 525-542 (2014).
59. Lokhorst, H. M. et al. Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma. J Clin. Oncol. 31 (Suppl.), 8512 (2013).
60. Hoffman, L. M. & Gore, L. Blinatumomab, a bi specific anti CD19/CD3 BiTE® antibody for the treatment of acute lymphoblastic leukemia: perspectives and current pediatric applications. Front. Oncol. 4, 63 (2014).
61. Topp, M. S. et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 120, 5185-5187 (2012).
62. Topp, M. S. et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 16, 57-66 (2014).
63. Topp, M. S. et al. Phase II trial of the anti CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J. Clin. Oncol. 32, 4134-4140 (2014).
64. Viardot, A. et al. Treatment of relapsed/refractory diffuse large B-cell lymphoma with the bispecific T-cell engager (BiTE) antibody construct blinatumomab: primary analysis results from an open-label, phase 2 study. ASH Annu. Meet. Abstr. 124, 4460 (2014).
65. Laszlo, G. S. et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood 123, 554-561 (2014).
66. Williams, K. M., Hakim, F. T. & Gress, R. E. T cell immune reconstitution following lymphodepletion. Semin. Immunol. 19, 318-330 (2007).
67. Hakim, F. T. et al. Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood 90, 3789-3798 (1997).
68. Maus, M. V., Grupp, S. A., Porter, D. L. & June, C. H. Antibody modified T cells: CARs take the front seat for hematologic malignancies. Blood 17, 2625-2635 (2014).
69. Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733 (2011).
70. Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).
71. Kochenderfer, J. N. et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33, 540-549 (2015).
72. Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507-1517 (2014).
73. Davila, M. L. et al. Efficacy and toxicity management of 19 28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25 (2014).
74. Vivier, E. et al. Innate or adaptive immunity? The example of natural killer cells. Science 331, 44-49 (2011).
75. Locatelli, F., Merli, P. & Rutella, S. At the bedside: innate immunity as an immunotherapy tool for hematological malignancies. J. Leukoc. Biol. 94, 1141-1157 (2013).
76. Ruggeri, L. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097-2100 (2002).
77. Venstrom, J. M. et al. HLA C dependent prevention of leukemia relapse by donor activating KIR2DS1. N. Engl. J. Med. 367, 805-816 (2012).
78. Cooley, S. et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 116, 2411-2419 (2010).
79. Hsu, K. C. et al. Improved outcome in HLA-identical sibling hematopoietic stem cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 105, 4878-4884 (2005).
80. Oevermann, L. et al. KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL. Blood 124, 2744-2747 (2014).
81. Torelli, G. F. et al. Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells. Haematologica 99, 1248-1254 (2014).
82. Miller, J. S. et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105, 3051-3057 (2005).
83. Rubnitz, J. E. et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J. Clin. Oncol. 28, 955-959 (2010).
84. Suntharalingam, G. et al. Cytokine storm in a Phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018-1028 (2006).
85. Croft, M., Benedict, C. A. & Ware, C. F. Clinical targeting of the TNF and TNFR superfamilies. Nature Rev. Drug Discov. 12, 147-168 (2013).
86. Yao, S., Zhu, Y. & Chen, L. Advances in targeting cell surface signalling molecules for immune modulation. Nature Rev. Drug Discov. 12, 130-146 (2013).
87. French, R. R., Chan, H. T., Tutt, A. L. & Glennie, M. J. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nature Med. 5, 548-553 (1999).
88. + T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nature Med. 5, 780-787 (1999).
89. Advani, R. et al. Phase I study of the humanized anti CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J. Clin. Oncol. 27, 4371-4377 (2009).
90. Beatty, G. L. et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612-1616 (2011).
91. Kohrt, H. E. et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 117, 2423-2432 (2011).
92. Coffman, R. L., Sher, A. & Seder, R. A. Vaccine adjuvants: putting innate immunity to work. Immunity 33, 492-503 (2010).
93. Rezvani, K. Post transplantation vaccination: concepts today and on the horizon. Hematology Am. Soc. Hematol. Educ. Program 11, 299-304 (2011).
94. Inoue, K. et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89, 1405-1412 (1997).
95. Miwa, H., Beran, M. & Saunders, G. F. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 6, 405-409 (1992).
96. Molldrem, J. J. et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J. Clin. Invest. 111, 639-647 (2003).
97. Greiner, J. et al. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Exp. Hematol. 30, 1029-1035 (2002).
98. Giannopoulos, K. et al. Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B cell chronic lymphocytic leukemia. Int. J. Oncol. 29, 95-103 (2006).
99. Molldrem, J. J. et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nature Med. 6, 1018-1023 (2000).
100. Rezvani, K. et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem cell transplantation for acute lymphoblastic leukemia. Blood 110, 1924-1932 (2007).
101. Greiner, J. et al. Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood 108, 4109-4117 (2006).
102. + progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95, 2198-2203 (2000).
103. Molldrem, J. et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 88, 2450-2457 (1996).
104. Keilholz, U. et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 113, 6541-6548 (2009).
105. Oka, Y. et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl Acad. Sci. USA 101, 13885-13890 (2004).
106. Schmitt, M. et al. RHAMM R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood 111, 1357-1365 (2008).
107. + T cell responses in patients with chronic lymphocytic leukemia. Leukemia 24, 798-805 (2010).
108. Qazilbash, M. H. et al. PR1 peptide vaccine-induced immune response is associated with better event-free survival in patients with myeloid leukemia. ASH Annu. Meet. Abstr. 110, 283 (2007).
109. Oka, Y. et al. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int. J. Hematol. 78, 56-61 (2003).
110. Rezvani, K. et al. Leukemia-associated antigen-specific T cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111, 236-242 (2008).
111. Uttenthal, B. et al. Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses. Br. J. Haematol. 164, 366-375 (2014).
112. + T cells in myeloid malignancies. Haematologica 96, 432-440 (2011).
113. Kuball, J. et al. Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909. Cancer Immunol. Immunother. 60, 161-171 (2011).
114. Maslak, P. G. et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T cell responses in patients with complete remission from acute myeloid leukemia. Blood 116, 171-179 (2010).
115. Figdor, C. G., de Vries, I. J., Lesterhuis, W. J. & Melief, C. J. Dendritic cell immunotherapy: mapping the way. Nature Med. 10, 475-480 (2004).
116. Kitawaki, T. et al. A phase I/IIa clinical trial of immunotherapy for elderly patients with acute myeloid leukaemia using dendritic cells co-pulsed with WT1 peptide and zoledronate. Br. J. Haematol. 153, 796-799 (2011).
117. Van Tendeloo, V. F. et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc. Natl Acad. Sci. USA 107, 13824-13829 (2010).
118. Cathcart, K. et al. A multivalent BCR-ABL fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 103, 1037-1042 (2004).
119. Bocchia, M. et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 365, 657-662 (2005).
120. Rojas, J. M., Knight, K., Wang, L. & Clark, R. E. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia 21, 2287-2295 (2007).
121. Jain, N. et al. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer 115, 3924-3934 (2009).
122. Rojas, J. M. et al. BCR-ABL peptide vaccination in healthy subjects: immunological responses are equivalent to those in chronic myeloid leukaemia patients. Leukemia Res. 35, 369-372 (2011).
123. Miller, R. A., Maloney, D. G., Warnke, R. & Levy, R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N. Engl. J. Med. 306, 517-522 (1982).
124. Bendandi, M. et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nature Med. 5, 1171-1177 (1999).
125. Inoges, S. et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J. Natl Cancer Inst. 98, 1292-1301 (2006).
126. Redfern, C. H. et al. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J. Clin. Oncol. 24, 3107-3112 (2006).
127. Ai, W. Z., Tibshirani, R., Taidi, B., Czerwinski, D. & Levy, R. Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma. Blood 113, 5743-5746 (2009).
128. Levy, R. et al. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. J. Clin. Oncol. 32, 1797-1803 (2014).
129. Schuster, S. J. et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J. Clin. Oncol. 29, 2787-2794 (2011).
130. Freedman, A. et al. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J. Clin. Oncol. 27, 3036-3043 (2009).
131. Bendandi, M. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nature Rev. Cancer 9, 675-681 (2009).
132. Muraro, E., Martorelli, D. & Dolcetti, R. Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas. Hum. Vaccin. Immunother. 9, 1078-1083 (2013).
133. Choudhury, B. A. et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood 93, 780-786 (1999).
134. + acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells. Blood 94, 2048-2055 (1999).
135. Li, L. et al. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts. Int. J. Oncol. 28, 855-861 (2006).
136. Ossenkoppele, G. J. et al. Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells. Leukemia 17, 1424-1426 (2003).
137. Dessureault, S. et al. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Ann. Surg. Oncol. 14, 869-884 (2007).
138. Rousseau, R. F. et al. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood 107, 1332-1341 (2006).
139. Wierda, W. G. et al. A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154. Leukemia 24, 1893-1900 (2010).
140. Wierda, W. G. et al. CD40 ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 96, 2917-2924 (2000).
141. Maier, T. et al. Vaccination of patients with cutaneous T cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood 102, 2338-2344 (2003).
142. + regulatory T cells toward an antileukemia response. Leukemia 22, 1007-1017 (2008).
143. Di Nicola, M. et al. Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood 113, 18-27 (2009).
144. Rosenblatt, J. et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin. Cancer Res. 19, 3640-3648 (2013).
145. Rosenblatt, J. et al. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood 117, 393-402 (2011).
146. Brody, J. D. et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J. Clin. Oncol. 28, 4324-4332 (2010).
147. Witzig, T. E. et al. A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma. Am. J. Hematol. 88, 589-593 (2013).
148. Burkhardt, U. E. et al. Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J. Clin. Invest. 123, 3756-3765 (2013).
149. Borrello, I., Sotomayor, E. M., Cooke, S. & Levitsky, H. I. A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum. Gene Ther. 10, 1983-1991 (1999).
150. Smith, B. D. et al. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin. Cancer Res. 16, 338-347 (2010).
151. Ho, V. T. et al. Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc. Natl Acad. Sci. USA 106, 15825-15830 (2009).
152. Surh, C. D. & Sprent, J. Regulation of mature T cell homeostasis. Semin. Immunol. 17, 183-191 (2005).
153. Norde, W. J., Hobo, W., van der Voort, R. & Dolstra, H. Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention. Blood 120, 728-736 (2012).
154. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
155. Ansell, S. M. et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin. Cancer Res. 15, 6446-6453 (2009).
156. Bashey, A. et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 113, 1581-1588 (2009).
157. Davids, M. S. et al. A multicenter phase I study of CTLA-4 blockade with ipilimumab for relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. ASH Annu. Meet. Abstr. 124, 3964 (2014).
158. Wherry, E. J. T cell exhaustion. Nature Immunol. 131, 492-499 (2011).
159. Riches, J. C. et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 121, 1612-1621 (2013).
160. Yang, Z. Z. et al. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J. Clin. Invest. 122, 1271-1282 (2012).
161. Green, M. R. et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116, 3268-3277 (2010).
162. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
163. Armand, P. et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J. Clin. Oncol. 31, 4199-4206 (2013).
164. Ansell, S. M. et al. PD 1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372, 311-319 (2015).
165. Moskowitz, C. H. et al. PD 1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE-013). ASH Annu. Meet. Abstr. 124, 290 (2014).
166. Lesokhin, A. M. et al. Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. ASH Annu. Meet. Abstr. 124, 291 (2014).
167. Greaves, P. & Gribben, J. G. The role of B7 family molecules in hematologic malignancy. Blood 121, 734-744 (2013).
168. Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133 (2013).
169. Vey, N. et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 120, 4317-4323 (2012).
170. Benson, D. M. Jr et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 120, 4324-4333 (2012).
171. Korde, N. et al. A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica 99, e81-e83 (2014).
172. Balkwill, F., Montfort, A. & Capasso, M. B regulatory cells in cancer. Trends Immunol. 34, 169-173 (2013).
173. Prince, H. M. et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T cell lymphoma. J. Clin. Oncol. 28, 1870-1877 (2010).
174. reg. Blood 122, 2185-2194 (2013).
175. Bulliard, Y. et al. Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J. Exp. Med. 210, 1685-1693 (2013).
176. Simpson, T. R. et al. Fc dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210, 1695-1710 (2013).
177. Westin, J. R. et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 15, 69-77 (2014).
178. Davis, T. A. et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J. Clin. Oncol. 18, 3135-3143 (2000).
179. Bachanova, V. et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 25, 3855-3863 (2014).
180. Spisek, R. et al. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J. Exp. Med. 204, 831-840 (2007).
181. Richter, J. et al. Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. Blood 121, 423-430 (2013).
182. Bachireddy, P. et al. Reversal of in situ T cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood 123, 1412-1421 (2014).
183. Jenq, R. R. & van den Brink, M. R. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nature Rev. Cancer 10, 213-221 (2010).
184. Wu, C. J. & Ritz, J. Induction of tumor immunity following allogeneic stem cell transplantation. Adv. Immunol. 90, 133-173 (2006).
185. Topalian, S. L., Weiner, G. J. & Pardoll, D. M. Cancer immunotherapy comes of age. J. Clin. Oncol. 29, 4828-4836 (2011).
186. Ribeiro, D., Melao, A. & Barata, J. T. IL 7R mediated signaling in T-cell acute lymphoblastic leukemia. Adv. Biol. Regul. 53, 211-222 (2013).
187. Zenatti, P. P. et al. Oncogenic IL7R gain of function mutations in childhood T-cell acute lymphoblastic leukemia. Nature Genet. 43, 932-939 (2011).
188. Digel, W. et al. Human interleukin-7 induces proliferation of neoplastic cells from chronic lymphocytic leukemia and acute leukemias. Blood 78, 753-759 (1991).
189. Swainson, L. et al. IL 7 induced proliferation of recent thymic emigrants requires activation of the PI3K pathway. Blood 109, 1034-1042 (2007).
190. Barata, J. T. et al. Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells. J. Exp. Med. 200, 659-669 (2004).
191. Döhren-von Minden, M. et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 489, 309-312 (2012).
192. Davis, R. E. et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463, 88-92 (2010).
193. Byrd, J. C. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369, 32-42 (2013).
194. Wang, M. L. et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 369, 507-516 (2013).
195. Vanneman, M. & Dranoff, G. Combining immunotherapy and targeted therapies in cancer treatment. Nature Rev. Cancer 12, 237-251 (2012).
196. + T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 18, 485-498 (2010).
197. Knight, D. A. et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J. Clin. Invest. 123, 1371-1381 (2013).
198. Akbay, E. A. et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 3, 1355-1363 (2013).
199. Preudhomme, C. et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N. Engl. J. Med. 363, 2511-2521 (2010).
200. Savani, B. N. et al. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant. 36, 1009-1015 (2005).
201. Stewart, A. K. How thalidomide works against cancer. Science 343, 256-257 (2014).
202. James, D. F. et al. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the Chronic Lymphocytic Leukemia Research Consortium. J. Clin. Oncol. 32, 2067-2073 (2014).
203. Kronke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301-305 (2014).
204. Ramsay, A. G. et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J. Clin. Invest. 118, 2427-2437 (2008).
205. Shanafelt, T. D. et al. Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). Blood 121, 4137-4141 (2013).
206. Galustian, C. et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol. Immunother. 58, 1033-1045 (2009).
207. + regulatory T cells. J. Immunol. 177, 6598-6602 (2006).
208. H1 selective pressure in T lymphocytes. Blood 122, 2539-2549 (2013).
209. Heslop, H. E. et al. Long-term outcome of EBV-specific T cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115, 925-935 (2010).
210. Bollard, C. M. et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J. Clin. Oncol. 32, 798-808 (2014).
211. Rajasagi, M. et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood 3, 453-462 (2014).
212. Fritsch, E. F. et al. HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol. Res. 2, 522-529 (2014).